HRTX News and Press, Heron Therapeutics Inc. From 12/22/21

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics (NASDAQ: HRTX) saw its shares rise 14.9% this week. The stock, which closed at $8.68 last Friday, climbed to as high as $9.97 on Thursday. The stock is still down more than 54% for the year and is closer to its 52-week low of $8.29 than its high of $22.40. Ima...

Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward. Short-sellers, or inves...

Ensysce Biosciences (NASDAQ:ENSC) +83%. Inspira Technologies (NASDAQ:IINN) +59%. American Virtual Cloud Technologies (NASDAQ:AVCT) +29% announces significant projected revenue growth of Kandy, its cloud communications platform. Siyata Mobile (NASDAQ:SYTA) +28%. Digital Brands (NASDAQ:DBG...

Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF® - Approval provides a significantly broader indication for ZYNRELEF, now covering approximately 7 million procedures a year - - Conference call and webcast today, December 9, 2...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics (NASDAQ:HRTX) announces the submission of its New Drug Application (NDA) to the FDA for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults. The NDA filing includes data demonstrating the bioequivalence of HTX-01...

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA PR Newswire SAN DIEGO , Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focu...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...